Drug Trial Radar · NCT00160173
Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy
Last checked: Nov 20, 2026Latest source record: Sep 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
Dec 2, 2004
Primary completion
Sep 6, 2005
Study completion Sep 6, 2005
Sponsor
- Lead sponsor
- ASCEND TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Solvay Pharmaceuticals
- First posted
- Sep 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 45 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.
Conditions
- Postmenopausal Symptoms
Interventions
EstrogelDrug
PlaceboOther
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
109 sites in 1 country. Site status is shown where the registry gives one.
Site 112
Birmingham, Alabama
Site 74
Mobile, Alabama
Site 20
Montgomery, Alabama
Site 34
Tucson, Arizona
Site 68
Tucson, Arizona
Site 5
Jonesboro, Arkansas
Site 88
Little Rock, Arkansas
Site 95
Little Rock, Arkansas
Site 104
Carmichael, California
Site 42
Encinitas, California
Site 21
San Diego, California
Site 37
San Diego, California
Site 78
San Diego, California
Site 82
San Diego, California
Site 69
Avon, Connecticut
Site 58
Bridgeport, Connecticut
Site 3
Groton, Connecticut
Site 72
Hartford, Connecticut
Site 54
New Britain, Connecticut
Site 79
Southport, Connecticut
Site 18
Waterbury, Connecticut
Site 97
West Hartford, Connecticut
Site 35
Aventura, Florida
Site 36
Aventura, Florida
Site 105
Clearwater, Florida
Site 49
Clearwater, Florida
Site 91
Daytona Beach, Florida
Site 57
Melbourne, Florida
Site 109
Miami, Florida
Site 39
Pinellas Park, Florida
Site 107
Spring Hill, Florida
Site 100
Tampa, Florida
Site 77
West Palm Beach, Florida
Site 61
Alpharetta, Georgia
Site 81
Alpharetta, Georgia
Site 28
Atlanta, Georgia
Site 93
Atlanta, Georgia
Site 55
Decatur, Georgia
Site 13
Douglasville, Georgia
Site 87
Powder Springs, Georgia
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.